Trium Capital discloses 11% stake in Mural Oncology
PositiveFinancial Markets

Trium Capital has announced that it holds an 11% stake in Mural Oncology, marking a significant investment in the biotech sector. This move is noteworthy as it highlights Trium's confidence in Mural's innovative approaches to cancer treatment, potentially paving the way for advancements in oncology and attracting further interest from investors.
— Curated by the World Pulse Now AI Editorial System